IRadimed Corporation reported record financial results for the fourth quarter (Q4) and full year (FY) 2025. Revenue for Q4 2025 reached USD 22.7 million, an increase of 17%. GAAP diluted earnings per share $(EPS)$ for Q4 was USD 0.50, up 25%, and non-GAAP diluted EPS was USD 0.54, up 23%. For the full year 2025, IRadimed Corporation reported GAAP diluted EPS of USD 1.75, an increase of 17%, and non-GAAP diluted EPS of USD 1.93, an increase of 16%. The company declared a regular quarterly cash dividend of USD 0.20 per share for Q4 2025, payable on March 6, 2026, representing an increase from USD 0.17 per share. IRadimed Corporation highlighted the successful transition to its new Orlando facility during 2025 and reaffirmed its commitment to innovation and operational efficiency. For 2026, IRadimed Corporation expects full-year revenue in the range of USD 91.0 million to USD 96.0 million, GAAP diluted EPS between USD 1.90 and USD 2.05, and non-GAAP diluted EPS between USD 2.06 and USD 2.21. First quarter 2026 revenue guidance is in the range of USD 21.0 million to USD 22.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IRadimed Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-012356), on February 10, 2026, and is solely responsible for the information contained therein.